BHC Heads Into Earnings With Activists on the Register and a 47% Historical Beat Reaction

BHC reports Q3 results today with one of the more unusual ownership structures in mid-cap pharma: two active 13D filers holding more than a quarter of the company between them.

Paulson & Co. is the largest declared holder at 19.1% of the class, having more than doubled its stake from 8.9% in a series of filings. Alex Meruelo holds a further 9.99% under his own 13D. Both filings carry activist intent, meaning these are not passive positions. The register also shows Icahn Partners previously held 9.4% before a filing that left its current stake undisclosed, a holder can drop below 5% without filing again. As a group, the activist register and the concentration of the top holders make the earnings print a more consequential event than the modest short interest level alone would suggest. Stakes are as-last-disclosed around the 5% threshold.

The lending market tells a relaxed story heading into the print. Short interest is only 2.2% of the free float, and availability is exceptionally loose at 2,239%, meaning shares available to borrow dwarf the current short position by a wide margin. Cost to borrow is 0.69%, near the low end of its recent range. This is not a stock where bears are pressing hard. The ORTEX short score of 34 sits in the 65th percentile of the utilization rank, but the overall lending setup reflects no meaningful squeeze pressure.

Options positioning has shifted in a direction that supports the stock's recent price action. The put/call ratio of 1.74 is actually below its 20-day average of 1.79, running roughly 1.4 standard deviations lighter than the recent norm on the put side. For a name where puts have structurally dominated, that modest easing of defensive demand coincides with a 10% single-day gain on October 28 and a 22% rise over the past month to $6.92.

The analyst community is lukewarm but not hostile. The consensus is a hold across six analysts, with a mean price target of $7.63, around 10% above the current price. The most recent target cuts came from RBC Capital in April and Barclays in February, both trimming to reflect ongoing revenue headwinds without changing their neutral ratings. The bull case rests on Solta Medical's 28% year-on-year growth and Canadian market strength. Bears point to a 14% revenue decline in Latin America, international weakness versus consensus, and a projected 7% revenue drop by 2027 tied to IRA headwinds. Valuation is notable: the earnings yield factor ranks in the 100th percentile of the ORTEX universe, reflecting how compressed the share price has become relative to earnings power.

One piece of historical context stands out. The last two earnings prints produced one-day moves of 33% and 47% respectively. That pattern, in either direction, makes today's print a high-variance event for a stock that has already moved sharply in the run-up. The earnings report will test whether the operating improvements that drove those reactions have continued, and whether the activist holders' thesis is finding confirmation in the underlying numbers.